- Exousia Pro (OTC PINK: MAJI) reveals groundbreaking findings from Glioblastoma study.
- NANOG Expression therapy significantly boosts GBM cell death when combined with standard treatment, temozolomide (TMZ).
- The combined therapy targets cancer stem cell resistance, enhancing Glioblastoma treatment efficacy.
Exousia Pro, Inc. (OTC PINK: MAJI), a clinical-stage biotechnology company, has announced significant advancements in their Glioblastoma (GBM) study. During a Spaces interview, Chief Science Officer Dr. Marvin Hausman discussed the published research showcasing the promising results of their NANOG Expression therapy.
The study highlights that when used alone, temozolomide (TMZ), even at its maximum concentration, eliminated less than 20% of GBM cells. However, the combination of TMZ with shRNA targeting either NANOG or OCT4 resulted in a marked increase in cell death rates. This combination therapy has shown particular effectiveness in reducing the resistance of cancer stem cells in Glioblastoma.
Dr. Hausman emphasized the potential of this combination approach in overcoming Glioblastoma treatment challenges, indicating a significant shift in treatment efficacy. The research underlines the enhancement achieved by coupling traditional treatment with advanced gene-targeting techniques.
Exousia Pro's innovative approach involves using exosomes for the treatment of cancer, utilizing a patented manufacturing process with plant-based materials. This breakthrough adds a promising tool in the fight against Glioblastoma and represents a step forward in oncology treatment development.
